AUS
NZ
UK
CA
USA
IND
Highlights
- Promising Trial Data: Azer-cel achieves a 57% complete response rate in relapsed lymphoma patients.
- Enhanced Immune Response: The addition of IL-2 boosts T-cell proliferation, aiding patient recovery.
- Long-Lasting Remissions: Some patients remain in complete remission for over ten months.
Imugene (ASX:IMU) has shared encouraging results from its ongoing Phase 1b clinical trial of Azer-cel, a CD19 CAR-T therapy designed for patients with relapsed lymphoma. The latest findings, presented at the 2025 Tandem Meetings in Honolulu, reveal a 57% complete response rate, meaning more than half of the treated patients had no detectable lymphoma after therapy.
Dr. Paul Woodard, the company’s chief medical officer, expressed optimism about the trial outcomes, emphasizing the importance of achieving durable remissions in individuals who have undergone multiple prior treatments. One patient remains in complete remission for over ten months, showcasing the therapy’s potential in delivering long-lasting benefits.
Enhancing Efficacy with IL-2
A key aspect of Azer-cel’s promising performance is the incorporation of a low dose of IL-2, which plays a crucial role in T-cell proliferation. Managing director and CEO Leslie Chong highlighted that this approach strengthens the patient’s immune response, improving their ability to fight cancer effectively.
For patients facing relapsed and refractory lymphoma, where standard treatments have been exhausted, these results provide new hope. Azer-cel’s ability to achieve complete responses in more than half of the participants reinforces its potential as a breakthrough therapy in the CAR-T space.
Addressing a Critical Unmet Need
The need for innovative therapies in relapsed lymphoma remains urgent. Azer-cel is being developed specifically for individuals who have relapsed after multiple lines of treatment, a group that typically has limited options and poor prognosis.
Dr. Woodard underscored the significance of the trial’s findings, stating that the long-term remissions observed in some patients demonstrate the effectiveness of Azer-cel in tackling aggressive lymphoma cases. These insights contribute to the growing body of evidence supporting the potential of CAR-T therapies in transforming cancer treatment.
As the trial progresses, further updates will provide additional clarity on the long-term benefits and safety profile of Azer-cel, potentially paving the way for broader clinical applications.
